The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly medicine initially developed as a treatment ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

The Food and Drug Administration has approved Zepbound to treat obstructive sleep apnea for people who are moderately or ...

The bottom line: We're maintaining our $580 fair value estimate for Eli Lilly, and the firm's tirzepatide molecule (diabetes drug Mounjaro and obesity/sleep apnea drug Zepbound) and ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep ...

On Friday, the federal agency green-lighted Eli Lilly’s Zepbound drug for the use, approving a prescription medicine suited for adults suffering from moderate to severe obstructive sleep apnea ...